Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 5, 1997, Pages 467-472

  Erickson Miller, Connie L ^a,e   May, Richard D ^b   Tomaszewski, Joseph ^c   Osborn, Blaire ^c   Murphy, Martin J ^a   Page, John G ^b   Parchment, Ralph E ^a,d  

^a Cancer Prevention Institute Dayton   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e SmithKline Beecham   (United States)

Author keywords

Hematopoiesis; Myelosuppression; Neutropenia; Pharmacodynamics; Topoisomerase I

Indexed keywords

9 AMINOCAMPTOTHECIN; CAMPTOTHECIN; TOPOTECAN;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; COLONY FORMATION; COLONY FORMING UNIT GM; DOG; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC TISSUE; HUMAN; HUMAN CELL; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW CELLS; CAMPTOTHECIN; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; DNA TOPOISOMERASES, TYPE II; DOGS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-3; MICE; RECOMBINANT PROTEINS; TOPOTECAN;

EID: 0031054593     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050600     Document Type: Article

References (40)

1. Burke TG, Mi Z (1993) Preferential binding of carboxylate form of camptothecin by human serum albumin. Anal Biochem 21:285
2. Burke TG, Mi Z (1994) The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37:40
3. Dahut W, Harold N, Takimoto C, Allegra C, Chen A. Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W, Grem J (1996) Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14: 1236
4. Dixit R, Lopez R, Douglas T (1992) The IV infusion toxicity of 9-amino-20S-camptothecin (9-AC, NSC-603071) in beagle dogs. Proc Am Assoc Cancer Res 33:A3278
5. Dixit R, Lopez R, Muellner P, Mowry B, Fanska C, Morton T, Arneson D, Stedham M, Smith A, Osborn B, Tomaszewski JE (1993) A species comparison of toxicity and pharmacokinetics of 9-amino-20S camptothecin in rodents and dogs. Proc Am Assoc Cancer Res 34:A2552
6. Du DL, Volpe DA, Grieshaber CK, Murphy MJ (1990) In vitro myelotoxicity of 2′,3′-dideoxynucleosides on human hematopoietic progenitor cells. Exp Hematol 18:832
7. Du DL, Volpe DA, Grieshaber CK, Murphy MJ (1991) Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Invest New Drugs 9:149
8. Du DL, Volpe DA, Grieshaber CK, Murphy MJ (1992) In vitro toxicity of 3′-azido-3′-deoxythymidine (AZT), Carbovir, and 2′,3′-dideoxythymidine (d4T) to human and murine hematopoietic progenitor cells. Br J Haematol 80:437
9. Eng W-K, Faucette L, Johnson RK, Sternglanz R (1988) Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34:755
10. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK (1990) Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:471
11. Ferguson PJ, Fisher MH, Stephenson J, Li D-H, Zhou B-S, Cheng Y-C (1988) Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48:5956
12. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD (1994) Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34:171
13. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046
14. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS Jr, Silber R, Potmesil M (1991) Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51:3052
15. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461
16. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC, Noe DA (1992) Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706
17. Gupta RS, Gupta R, Eng W-K, Lock RB, Ross WE, Hertzberg RP Caranfa MJ, Johnson RK (1988) Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48:6404
18. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, Blum RH (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12:553
19. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31:229
20. Hsiang H, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, Potmesil M (1989) DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4385
21. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465
22. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, Estey EH (1993) Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146
23. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ. McCabe FL, Faucette LF, Johnson RK, Hertzberg RP (1991) Synthesis of water-soluble (aminoalkyl)-camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34:98
24. McCabe FL, Johnson RK (1994) Comparative activity of oral and parenteral topotecan in murine tumor models. Cancer Invest 12:308
25. Mi Z, Burke TG (1994) Differential interaction of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325
26. Mi Z, Burke TG (1994) Marked interspecies variations concerning the interaction of camptothecin with serum albumin: a frequency-domain fluorescence spectroscopic study. Biochemistry 33:12540
27. Muggia FM, Creaven PJ, Hansen H, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56:515
28. Parchment RE , Huang M, Erickson-Miller CL (1993) Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol 21:241
29. Parchment RE, Volpe DA, LoRusso PM, Erickson-Miller CL, Murphy MJ Jr, Grieshaber CK (1994) In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine and canine marrow. J Natl Cancer Inst 86:273
30. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, Avery L, Meyer WH (1994) Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12:539
31. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WR Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC (1992) Phase I and pharmacological study of topotecan: a novel topoisomerase inhibitor. J Clin Oncol 10:647
32. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F, Kelsen D (1993) Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors with attempt at dose-intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499
33. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271
34. Verweij J, Lund B, Beijnen J, Planting A, deBoer-Dennert M, Koier I, Rosing H, Hansen H (1993) Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4:673
35. Volpe DA, Du DL, Pohl KP, Campbell JP, Murphy MJ (1991) Utility of human bone marrow obtained incidental to orthopedic surgery for hematopoietic clonal assays. Pathobiology 59:53
36. Volpe DA, Du DL, Zurlo MG, Mongelli N, Murphy MJ (1992) Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine, and murine hematopoietic progenitor cells. Invest New Drugs 10:255
37. Volpe DA, Du DL, Verhoef V, Murphy MJ (1993) Myelotoxicity of rifabutin and 3′-azido-3′-deoxythymidine (AZT), alone and in combination, to human hematopoietic progenitor cells in vitro. Pathobiology 61:77
38. Volpe DA, Du DL, Grieshaber CK, Murphy MJ (1994) In vitro characterization of the myelotoxicity of cyclopentenyl cytosine (CPE-C). Cancer Chemother Pharmacol 34:103
39. Wall ME, Wani NC, Cook CE, Palmer KH, McPhail AT, Sim GA (1966) Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkyloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 94:3888
40. Wani MC, Ronman PE, Lindley JT, Wall ME (1980) Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 23:554